Talk:Golimumab

This is the talk page for discussing improvements to the Golimumab article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Golimumab.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Wiki Education Foundation-supported course assignment

This article is or was the subject of a Wiki Education Foundation-supported course assignment. Further details are available on the course page. Student editor(s): Jcolls4.

Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT (talk) 22:31, 16 January 2022 (UTC)[reply]

IV also approved and being trialled

EULAR: IV Golimumab Succeeds in AS 2017 says intravenous injection also approved for RA, and being trialled for AS. (The IV dosing is 2mg/kg every 8 weeks (vs 50mg/month for subcutaneous) so maybe there are adverse reactions to subcutaneous injections.) - Rod57 (talk) 07:21, 22 June 2017 (UTC)[reply]

External links modified

Hello fellow Wikipedians,

I have just modified one external link on Golimumab. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:

Added archive https://web.archive.org/web/20080930094443/http://sev.prnewswire.com/retail/20080415/NYTU07615042008-1.html to http://sev.prnewswire.com/retail/20080415/NYTU07615042008-1.html

When you have finished reviewing my changes, you may follow the instructions on the template below to fix any issues with the URLs.

This message was posted before February 2018. After February 2018, "External links modified" talk page sections are no longer generated or monitored by InternetArchiveBot. No special action is required regarding these talk page notices, other than regular verification using the archive tool instructions below. Editors have permission to delete these "External links modified" talk page sections if they want to de-clutter talk pages, but see the RfC before doing mass systematic removals. This message is updated dynamically through the template {{source check}} (last update: 5 June 2024).

If you have discovered URLs which were erroneously considered dead by the bot, you can report them with this tool.
If you found an error with any archives or the URLs themselves, you can fix them with this tool.

Cheers.—InternetArchiveBot (Report bug) 22:28, 20 October 2017 (UTC)[reply]

Recommended or not for patients who failed other TNFi treatments?

This Wikipedia entry states that: "National Institutes for Health and Care Excellence (NICE) stated that treatment with golimumab is not recommended for RA patients who have failed prior TNFi treatment"

However, upon checking the quoted reference (doi:10.1007/s40273-013-0052-7), its last sentece states: "The Appraisal Committee concluded that golimumab should be recommended in combination with methotrexate as an option for patients with severe active RA who have failed on conventional DMARDs, or who have failed on a TNF-α inhibitor and are contraindicated to or withdrawn from rituximab." [both emphases added]

So while Wikpedia recommends against using this kind of TNFi when other failed, the NICE meta-analysis states that it's a fair try in combination with MTX.

I have a PhD in biochemistry so I think I am able to read the abstract of a scientific paper and understand it (I don't have full access to the paper and am not willing to shell $50 to read it in full). Am I missing something, or should the entry be revised?

79.243.58.106 (talk) 07:05, 19 October 2018 (UTC) Alexandru Constantinescu, Ph.D., 2018-10-19[reply]